Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes

References

• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299.
   PubMed Web of Science ®Google Scholar
• Merkel D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013;88:130–134.
   PubMed Web of Science ®Google Scholar
• Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis. 2013;15:652–657.
   PubMed Web of Science ®Google Scholar
• Toma A, Fenaux P, Dreyfus F, et al. Infections in myelodysplastic syndromes. Haematologica. 2012;97:1459–1470.
   PubMed Web of Science ®Google Scholar
• Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85:130–138.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon, France: IARC; 2008.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Stolzel F, Kramer M, Mohr B, et al. Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome. Leukemia. 2014;28:723–725.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases Society of America. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161:397–401.
   PubMed Web of Science ®Google Scholar
• (CDC) CfDC. CDC/NHSN surveillance definitions for specific types of infections; 2016. Available from: http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf
   Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Reilly M, Andresen D, et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J. 2011;41:90–101.
   PubMed Web of Science ®Google Scholar
• Kenealy M, Seymour JF, Benson W, et al. P-272 The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial. Leuk Res. 2013:37:S145.
   Web of Science ®Google Scholar
• Kenealy MK, Seymour JF, Linda C, et al. The tolerability of combination therapy with thalidomide and 5-azacitidine in patients with advanced myelodysplastic syndromes (MDS). Blood. 2015;114:1749–1749.
   Google Scholar
• Dickinson MJ, Herbert K, Sardjono C, et al. Final analysis of a phase II study of intrapatient dose-escalation of eltrombopag in patients receiving azacitidine for myelodysplasia/AML. Blood. 2014;124:4657–4657.
   Web of Science ®Google Scholar
• Falantes JF, Calderon C, Marquez-Malaver FJ, et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk. 2014;14:80–86.
   PubMed Web of Science ®Google Scholar
• Horwedel TA, Bowman LJ, Saab G, et al. Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant. Transpl Infect Dis. 2014;16:261–269.
   PubMed Web of Science ®Google Scholar
• Torda A, Chong Q, Lee A, et al. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16:751–759.
   PubMed Web of Science ®Google Scholar
• Kimura S, Akahoshi Y, Nakano H, et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect. 2014;69:13–25.
   PubMed Web of Science ®Google Scholar
• Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44:1283–1297.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res. 2011;35:499–503.
   PubMed Web of Science ®Google Scholar
• Xie M, Jiang Q, Xie Y. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Clin Lymphoma Myeloma Leuk. 2015;15:22–28.
   PubMed Web of Science ®Google Scholar